A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy

NCT06927375 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Thyroid-Associated Ophthalmopathy

Interventions

DRUG: Tocilizumab(400mg) combined with Flupentixol Melitracen(0.5mg:10mg)
DRUG: Tocilizumab(400mg)

Sponsor

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University